April 29 was, by nearly every conventional measure, one of the best earnings days in Teradyne’s corporate history. Revenue of $1.282 billion — up 87% year-over-year, clearing the Street’s $1.21 billion estimate by a meaningful margin. Non-GAAP EPS of $2.56 against a consensus around $2.08, a 23% beat. The Semiconductor Test division crossed $1.1 billion for the first time ever. Non-GAAP EPS grew 241% year-over-year. Management noted that roughly 70% of quarterly revenue was AI-driven, up from approximately 60% in the prior quarter. Any reasonable observer looking at those numbers would call it a blowout.

The stock dropped 19% on the day.

This is the part of markets that rarely gets discussed honestly. The headline result is almost never what drives the price reaction. What moves the stock is the gap between what participants expected — not just from the quarter, but from the forward outlook — and what they actually received. Teradyne delivered something the market wasn’t positioned for.

Where It Actually Broke Down

TER had already more than doubled year-to-date heading into the report. That context matters more than most people acknowledge. A stock up 107% on a single thesis — AI test equipment demand — isn’t being valued against analyst consensus. It’s being valued against an unspoken expectation that the momentum continues at roughly the same slope. When guidance comes in below that expectation, the correction isn’t gradual. It’s abrupt.

Here’s what management actually guided for Q2 2026: revenue of $1.15 billion to $1.25 billion — a sequential step-down from the record $1.282 billion just reported. Non-GAAP EPS midpoint of approximately $2.00, versus the $2.56 just delivered. Management was transparent about the reason: AI program timing, and a first-half revenue concentration that runs 55–60% weighted toward Q1. The back half of the year would need to carry significant weight.

That last point is what really moved the stock. Q1 wasn’t necessarily the beginning of a new sustained run-rate. It may have been the peak of a front-loaded demand cycle. At a P/E north of 100x, even a suggestion of that reads as a fundamental reset — and the market responded accordingly.

Worth noting: the full-year target management cited — $6 billion in revenue and $9.50–$11.00 in non-GAAP EPS — actually implies meaningful back-half acceleration. That tension between a soft Q2 guide and a confident full-year outlook is where the bull and bear cases diverge most sharply right now. Neither side is obviously wrong.

What the Options Market Had Already Figured Out

Heading into the report, TER options were pricing an expected move in the 12–15% range — elevated, but not extreme given the year-to-date run. What happened after the open was instructive. The decline was fast, opened with a gap, and showed no meaningful intraday recovery. That pattern is consistent with dealer delta-hedging on short calls that went deeply underwater simultaneously as the stock broke lower at the open.

Traders holding long calls into the announcement faced a compounded loss: the directional move worked against them, and implied volatility collapsed immediately after — the standard post-earnings vol crush. The options market had already assigned meaningful probability to a downside move despite the AI demand strength. That’s the part that gets missed when traders focus only on whether the company beat estimates. The put-call positioning going in was not structured for a clean continuation higher.

A defined-risk put spread positioned below the expected move range would have captured the guidance-driven decline without requiring a directional call in advance. The risk structure was available. The options flow was signaling it.

Three Ways to Think About What Comes Next

If you think the Q2 step-down is a timing issue, not a structural one: TER near $331 post-earnings represents a real discount to where institutional buyers were positioned a week prior. The Q2 guidance midpoint still implies roughly 84% year-over-year revenue growth — hardly a collapsing business. JPMorgan upgraded to Overweight on April 30, framing the valuation reset as an entry point. For traders who expect a recovery, a call spread in August expiration — defined risk, no margin exposure — gives directional participation without requiring a return to prior highs.

If you think the slowdown is real and durable: The math at a trailing P/E of approximately 109x and a PEG ratio above 23 leaves almost no room for disappointment. Any softening in the back half — hyperscaler capex hesitation, order timing shifts, export control friction — creates meaningful valuation compression. A bear put spread targeting the $290–$300 zone is a reasonable defined-risk expression of that view. The position doesn’t require a collapse. It only needs the deceleration to persist through Q3 guidance.

If you think the stock just consolidates from here: Implied volatility is now materially lower following the post-earnings move. A short iron condor in the May/June range — premium collected on both sides — suits traders who expect the stock to range-bound rather than trend. The $300 put and $360 call strikes are worth watching as the anchoring levels for open interest. That’s where the market appears to be drawing its current boundaries.

The Risk Layer

Seventy percent of revenue tied to a single demand theme is both the core bull thesis and the single largest point of vulnerability. There’s no hedging that concentration at the company level. If hyperscaler capital spending decisions shift — even temporarily — TER’s order book absorbs it directly. Export control risks flagged on the earnings call introduce a policy variable that’s genuinely difficult to model. And broader macro uncertainty in 2026 hasn’t resolved in any meaningful way. These aren’t remote possibilities. They’re known variables without a clear timeline.

Forward analyst consensus still projects roughly 11.5% revenue growth over the next 12 months. Hold that against the 87% just delivered. The debate isn’t whether Teradyne is growing — it clearly is. The debate is whether a test equipment company deserves a 100x-plus earnings multiple when the rate of growth is decelerating sharply. That’s the question the market is now working through in real time. There’s no clean answer yet.

The next earnings catalyst will either confirm the back-half acceleration management is projecting — or it won’t. Either way, that’s the moment that resolves the argument.